Kindred Biosciences Company Profile (NASDAQ:KIN)

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:KIN
  • CUSIP: N/A
  • Web: www.kindredbio.com
Capitalization:
  • Market Cap: $166.67 million
  • Outstanding Shares: 23,310,000
Average Prices:
  • 50 Day Moving Avg: $7.00
  • 200 Day Moving Avg: $6.01
  • 52 Week Range: $3.25 - $7.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.56
  • P/E Growth: -0.13
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.07 per share
  • Price / Book: 2.33
Profitability:
  • EBIDTA: ($23,170,000.00)
  • Return on Equity: -33.34%
  • Return on Assets: -32.23%
Debt:
  • Current Ratio: 23.24%
  • Quick Ratio: 23.24%
Misc:
  • Average Volume: 105,297 shs.
  • Beta: 0.54
  • Short Ratio: 1.55
 

Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) posted its earnings results on Thursday, May, 4th. The company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.34) by $0.04. View Kindred Biosciences' Earnings History.

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?

4 analysts have issued 12-month target prices for Kindred Biosciences' stock. Their predictions range from $7.50 to $10.00. On average, they anticipate Kindred Biosciences' share price to reach $8.50 in the next twelve months. View Analyst Ratings for Kindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 108,116 shares, an increase of 8.9% from the April 28th total of 99,281 shares. Based on an average daily volume of 70,354 shares, the short-interest ratio is presently 1.5 days.

Who are some of Kindred Biosciences' key competitors?

Who owns Kindred Biosciences stock?

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional investors include Park West Asset Management LLC (19.87%), Ariel Investments LLC (13.49%), Morgan Stanley (9.19%), Dimensional Fund Advisors LP (6.21%), EcoR1 Capital LLC (2.47%) and Renaissance Technologies LLC (2.29%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Institutional Ownership Trends for Kindred Biosciences.

Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?

Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, EcoR1 Capital LLC, Royce & Associates LP, Bank of America Corp DE, Granite Investment Partners LLC, Prudential Financial Inc. and TFS Capital LLC. View Insider Buying and Selling for Kindred Biosciences.

Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?

Kindred Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Morgan Stanley, Renaissance Technologies LLC, Vanguard Group Inc., UBS Group AG, Dimensional Fund Advisors LP, Zurcher Kantonalbank Zurich Cantonalbank and Acadian Asset Management LLC. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Insider Buying and Selling for Kindred Biosciences.

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Kindred Biosciences stock cost?

One share of Kindred Biosciences stock can currently be purchased for approximately $7.15.

Analyst Ratings

Consensus Ratings for Kindred Biosciences (NASDAQ:KIN) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (18.88% upside)

Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017FBR & CoInitiated CoverageOutperform -> Outperform$10.00HighView Rating Details
5/15/2017BMO Capital MarketsReiterated RatingHold$8.00N/AView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50N/AView Rating Details
8/13/2015Roth CapitalReiterated RatingHoldN/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Kindred Biosciences (NASDAQ:KIN)
Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)
Earnings History by Quarter for Kindred Biosciences (NASDAQ:KIN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.40 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ:KIN)
Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 66.01%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.00View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.00View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.94View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.45View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Kindred Biosciences (NASDAQ:KIN)
Latest Headlines for Kindred Biosciences (NASDAQ:KIN)
Source:
DateHeadline
americanbankingnews.com logoKindred Biosciences Inc (KIN) Short Interest Update
www.americanbankingnews.com - May 25 at 11:05 AM
finance.yahoo.com logoKindred Biosciences to Present at 7th Annual LD Micro Invitational
finance.yahoo.com - May 24 at 11:16 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 24 at 8:22 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Earns Outperform Rating from Analysts at FBR & Co
www.americanbankingnews.com - May 24 at 7:20 AM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Major Shareholder Buys $1,059,169.08 in Stock
www.americanbankingnews.com - May 15 at 10:34 PM
finance.yahoo.com logoEdited Transcript of KIN earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 6 at 6:12 PM
americanbankingnews.com logoKindred Biosciences Inc (KIN) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 9:38 PM
americanbankingnews.com logoBMO Capital Markets Reiterates Hold Rating for Kindred Biosciences Inc (KIN)
www.americanbankingnews.com - May 5 at 9:34 PM
americanbankingnews.com logoKindred Biosciences (KIN) Given Daily Media Sentiment Rating of -0.12
www.americanbankingnews.com - May 4 at 9:48 AM
reuters.com logoBRIEF-Kindred Biosciences announces Q1 loss per share $0.30
www.reuters.com - May 4 at 1:16 AM
seekingalpha.com logoKindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 1:16 AM
finance.yahoo.com logoInvestor Network: Kindred Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 8:16 PM
finance.yahoo.com logoKindred Biosciences Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:16 PM
finance.yahoo.com logoKindred Bio reports 1Q loss
finance.yahoo.com - May 3 at 8:16 PM
americanbankingnews.com logoKindred Biosciences (KIN) Receives Daily Coverage Optimism Score of -0.12
www.americanbankingnews.com - May 1 at 3:42 PM
finance.yahoo.com logoKindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses
finance.yahoo.com - May 1 at 1:03 PM
americanbankingnews.com logoKindred Biosciences (KIN) Given Daily News Sentiment Rating of -0.12
www.americanbankingnews.com - April 28 at 12:40 PM
americanbankingnews.com logoZacks: Analysts Expect Kindred Biosciences Inc (KIN) to Announce -$0.31 EPS
www.americanbankingnews.com - April 27 at 9:18 PM
americanbankingnews.com logoKindred Biosciences (KIN) Given News Sentiment Rating of 0.10
www.americanbankingnews.com - April 25 at 5:29 PM
finance.yahoo.com logoKindred Biosciences to Announce First Quarter 2017 Financial Results
finance.yahoo.com - April 24 at 11:50 AM
americanbankingnews.com logoKindred Biosciences (KIN) Getting Positive News Coverage, Report Finds
www.americanbankingnews.com - April 22 at 12:19 AM
americanbankingnews.com logo Brokerages Anticipate Kindred Biosciences Inc (KIN) Will Announce Quarterly Sales of $0.00
www.americanbankingnews.com - April 8 at 9:29 AM
americanbankingnews.com logoZacks: Brokerages Expect Kindred Biosciences Inc (KIN) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - April 6 at 5:37 PM
finance.yahoo.com logoKindred Biosciences to Present at 2017 Jefferies Animal Health Summit
finance.yahoo.com - March 16 at 6:56 PM
americanbankingnews.com logoPark West Asset Management Llc Purchases 4,200 Shares of Kindred Biosciences Inc (KIN) Stock
www.americanbankingnews.com - March 15 at 12:24 AM
finance.yahoo.com logoKindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotor Pathology
finance.yahoo.com - March 7 at 10:48 AM
finance.yahoo.com logoKindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results
finance.yahoo.com - March 1 at 5:50 PM
biz.yahoo.com logoQ4 2016 Kindred Biosciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 1 at 11:27 AM
finance.yahoo.com logoKindred Biosciences to Announce Fourth Quarter and Year-End 2016 Financial Results
finance.yahoo.com - February 22 at 12:24 PM
streetinsider.com logoKindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application
www.streetinsider.com - February 6 at 11:19 PM
reuters.com logoBRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz
www.reuters.com - February 6 at 6:17 PM
us.rd.yahoo.com logo9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted)
us.rd.yahoo.com - February 6 at 10:21 AM
finance.yahoo.com logoKindred Biosciences Receives Early Approval of Effectiveness Technical Section from FDA for Mirataz™ New Animal Drug Application
finance.yahoo.com - February 6 at 10:21 AM
zacks.com logoKindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%
www.zacks.com - January 16 at 8:35 AM
seekingalpha.com logoKindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of Pets
seekingalpha.com - January 14 at 12:26 AM
biz.yahoo.com logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - December 20 at 11:45 AM
biz.yahoo.com logoKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 7 at 6:14 PM
reuters.com logoBRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention
www.reuters.com - November 29 at 4:18 PM
finance.yahoo.com logoKindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention
finance.yahoo.com - November 29 at 4:18 PM
finance.yahoo.com logoKindred Biosciences to Present at 9th Annual LD Micro Investor Conference
finance.yahoo.com - November 18 at 5:25 PM
seekingalpha.com logoTracking Seth Klarman's Baupost Group Holdings - Q3 2016 Update
seekingalpha.com - November 16 at 9:29 AM
prnewswire.com logoKindred Biosciences Announces Third Quarter 2016 Financial Results
www.prnewswire.com - November 7 at 9:38 AM
finance.yahoo.com logoCoverage initiated on Kindred Biosciences by Ladenburg Thalmann
finance.yahoo.com - November 1 at 6:08 PM
finance.yahoo.com logoKindred Biosciences Is 'Setting The Pace In Animal Health Biologics'
finance.yahoo.com - November 1 at 6:08 PM
finance.yahoo.com logoKindred Biosciences to Announce Third Quarter 2016 Financial Results
finance.yahoo.com - October 24 at 11:07 AM
finance.yahoo.com logoKindred Biosciences (KIN) Looks Good: Stock Gains 5.6%
finance.yahoo.com - October 4 at 10:36 AM
streetinsider.com logoKindred Biosciences (KIN) Submits Safety Technical Section to FDA Related to Mirataz NADA
www.streetinsider.com - September 30 at 10:58 AM
finance.yahoo.com logoKindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference
finance.yahoo.com - September 21 at 9:58 AM
finance.yahoo.com logo5 Breakout Stocks for Excellent Returns
finance.yahoo.com - September 16 at 12:28 PM
finance.yahoo.com logoKindred Biosciences to Participate in a BIO Animal Biotech Summit Panel
finance.yahoo.com - September 15 at 8:52 PM

Social

Chart

Kindred Biosciences (KIN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff